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Abstract
The mechanisms leading to disability and the long-term efficacy and safety of disease modi-
fying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospec-
tive cohort of MS patients with standardized collection of demographic, clinical, MRI data
and body fluids that can be used to develop prognostic indicators and biomarkers of disease
evolution and therapeutic response. The Swiss MS Cohort (SMSC) is a prospective obser-
vational study performed across seven Swiss MS centers including patients with MS, clini-
cally isolated syndrome (CIS), radiologically isolated syndrome or neuromyelitis optica.
Neurological and radiological assessments and biological samples are collected every
6–12 months. We recruited 872 patients (clinically isolated syndrome [CIS] 5.5%, relapsing-
remitting MS [RRMS] 85.8%, primary progressive MS [PPMS] 3.5%, secondary progressive
MS [SPMS] 5.2%) between June 2012 and July 2015. We performed 2,286 visits (median
follow-up 398 days) and collected 2,274 serum, plasma and blood samples, 152 cerebrospi-
nal fluid samples and 1,276 brain MRI scans. 158 relapses occurred and expanded disabil-
ity status scale (EDSS) scores increased in PPMS, SPMS and RRMS patients
experiencing relapses. Most RRMS patients were treated with fingolimod (33.4%), natalizu-
mab (24.5%) or injectable DMDs (13.6%). The SMSC will provide relevant information
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regarding DMDs efficacy and safety and will serve as a comprehensive infrastructure avail-
able for nested research projects.
Introduction
Multiple sclerosis (MS) is a complex demyelinating disease of the central nervous system
(CNS) and represents the most common cause of acquired neurological disability in young
adults in developed countries [1]. The prevalence of MS in Western Europe and North Amer-
ica is approximately 1/1,000, with an incidence of 5–10 new cases per 100,000 individuals every
year [2]. The relatively early age of onset (approximately 30 years old) and the typically chronic
and disabling course result in a substantial socio-economic burden [3, 4]. Approximately
10,000 individuals are thought to be affected by this condition in Switzerland.
Our understanding of MS aetiology has greatly improved in the last 10–20 years. We now
know that a large number of genetic variants, together with several putative environmental
agents (including serum vitamin D levels, Epstein-Barr virus infection and smoking) determine
MS susceptibility [5, 6]. Immunological and pathological studies have provided evidence for an
important role played by the immune system in the demyelinating process seen in MS [7, 8].
Neuronal degeneration is also key and becomes especially evident in the progressive phase of
the disease, when brain atrophy and irreversible disability accumulation are more prominent
[7, 9]. This increasing knowledge has provided the rationale behind the development of several
disease modifying drugs (DMDs) in addition to the first generation of injectable DMDs (inter-
feron β-1b, interferon β-1a and glatiramer acetate). These include natalizumab, fingolimod,
dimethyl fumarate, teriflunomide and alemtuzumab [10–15].
Despite this, the mechanisms driving the occurrence of clinical relapses, disability accumu-
lation and the passage from the relapsing-remitting to the secondary progressive phase of the
disease are still elusive [16, 17]. In addition, although the number of available DMDs has
increased, their efficacy and safety need long-term evaluation. This cannot be achieved in the
traditional settings of clinical trials, which are usually limited in time and rarely designed as
“head to head” trials comparing different DMDs. Furthermore, prognostic factors associated
with response to treatments are lacking and their identification will be key to develop personal-
ized treatment strategies. Finally, biological markers able to monitor subclinical pathology and
treatment efficacy are lacking and strongly needed [18]. Long-term observational studies com-
bining the systematic acquisition of clinical data, imaging and laboratory measures can help us
respond to these unmet needs.
The Swiss MS Cohort-Study (SMSC) was initiated in 2010 and started recruiting in June
2012 with 4 specific aims. 1) To build and maintain a long-term cohort of MS patients in Swit-
zerland. 2) To conduct a systematic follow-up of these MS patients with standardized collection
of demographic, clinical, and MRI data as well as body fluids material. 3) To maintain and
improve the high standard of care of MS patients in Switzerland and elsewhere by assessing the
long term efficacy and safety profile of available DMDs for MS. 4) To build a comprehensive
infrastructure available for nested projects aimed at developing prognostic indicators and bio-
markers of disease evolution and therapeutic response.
Materials and Methods
The SMSC is a prospective multicentre cohort study performed across seven Swiss centres: the
Cantonal Hospital of Aarau, the University Hospitals of Basel, Berne, Geneva and Lausanne,
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Patient Recruitment and Inclusion Criteria
To be included in the study individuals need to be diagnosed with either relapsing-remitting MS
(RRMS), secondary-progressive MS (SPMS) or primary-progressive MS (PPMS) according to
the 2010 revised McDonald [19 or previous established diagnostic criteria (McDonald or Poser)
[20, 21]. Patients diagnosed with a clinically isolated syndrome (CIS), radiologically isolated syn-
drome (RIS) or neuromyelitis optica (NMO) can also be included [22, 23]. We aimed to build a
cohort of patients that was homogeneous and informative for the questions we wanted to answer.
Eligible criteria were: 1) absence of treatment with any MS specific DMD, or 2) need to either
begin or switch to a different DMD as judged by the treating physician, or 3) initiation of a new
DMD or current treatment with natalizumab or fingolimod, or 4) switch to a different DMD.
Patients are included in the SMSC only after a written informed consent is signed. Every effort is
made to reduce drop-outs to a minimum. If a patient moves to another place within Switzerland,
the original centre arranges a consultation with the nearest participating centre.
Baseline and Follow-Up Clinical Data Collection
Demographic and clinical variables collected at baseline include sex, date of birth, ethnicity,
family history of MS, pregnancy history, date of first MS symptom, date of second relapse,
number of relapses in the last two years, date of diagnosis, date of start of progression (if appli-
cable), current MS specific DMDs, concomitant medical conditions and medications. Stan-
dardized clinical assessments with functional system score and Expanded Disability Status
Scale (EDSS) calculation are performed by certified raters (http://www.neurostatus.net/). Every
patient is followed-up every 6 or 12 months +/-45 days as judged by the treating physician. The
occurrence of relapses, disability progression (as measured by the EDSS), DMDs initiation or
interruption, DMD related adverse events, additional medical conditions and concomitant
medications are recorded at each visit. Laboratory measures and evoked potentials are also per-
formed in a smaller fraction of patients.
Body Fluids Collection
Collection protocols for serum/plasma and cerebrospinal fluid (CSF) have been published by
consensus among 26 groups participating in the BioMS-eu network [24]. We apply these pro-
tocols to collect CSF and blood samples from SMSC patients. Collection of CSF samples is
optional and limited to patients undergoing a diagnostic lumbar puncture. In contrast, serum,
plasma and whole blood samples (available for DNA extraction) are collected from all patients
at each visit (aim is +/-8 days from visit). All samples are stored at -80 Celsius degrees in
alarmed controlled freezers. The operation and maintenance of the biobank follow the recom-
mendations of the Swiss Academy for Medical Sciences SAMS (http://www.samw.ch/en).
Peripheral blood mononuclear cells isolation may be performed as part of specific nested
projects.
The Swiss Multiple Sclerosis Cohort-Study
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Magnetic Resonance Imaging (MRI) Data
Acquisition of MRI is not mandatory within the SMSC. However, in Switzerland scans are reg-
ularly performed as part of standard care of MS patients, even in the absence of clinically evi-
dent disease activity. We aim to acquire cranial MRIs at least once a year in as many patients as
possible (ideally all patients). We also aim to perform all scans within +/-28 days from the col-
lection of clinical data and samples. A state of the art MRI protocol was agreed upon by all
SMSC centres and includes: 1) High-resolution isotropic T1-MPRage (3D) without gadolinium
(Gd); 2) 3D-FLAIR isotropic (if 3D acquisition not possible, 2D acquisition is accepted); 3)
Axial proton density weighting (PD), 3 mm slice thickness, no gap; 4) High-resolution isotro-
pic T1-MPRage (3D) post intravenous gadolinium (Gd) contrast administration (0.1 mmol per
kg body weight, 2D acquisition is also accepted). Alignment for all axial sequences is AC/PC.
Three D acquisition is performed on sagittal plane and magnet strengths of 1.5T or 3T are
accepted. Advanced MRI sequences (e.g. DTI, MTR, fMRI) may be added as part of nested
projects. MRI reading is performed locally and data are sent to the Medical Image Assessment
Centre (MIAC) in Basel via a safe internet upload for quality control, central storage, back up
and standardized analyses.
Data Management and Quality Checks
Each patient is identified using an anonymous ID code and all individual clinical data are docu-
mented using an SMSC specific electronic Case Report Form (eCRF) developed by Rodanotech
(Geneva) in collaboration with the coordinating centre. The system allows the anonymous
export of data to the central database and a rapid and clear visualization of major events during
the course of MS. All collected data (eCRF, MRI imaging, and banked samples) are merged at
the Clinical Trial Unit (CTU) in Basel. The whole set of clinical and MRI data, as well as sam-
pling information, is subject to several automatic and manual internal quality checks. When
inconsistencies are observed (e.g. EDSS is inconsistent with functional systems scores or SPMS
is diagnosed without evidence of earlier RRMS), queries are sent to the relative centre until the
discrepancy is successfully solved. A standardised and updated core data set is regularly pro-
vided and made available for nested projects. This study is registered with ClinicalTrials.gov,
number NCT02433028.
Results
Recruitment, Visits and Deviations from Protocol
A total of 872 patients have been recruited between June 2012 and July 2015 (Fig 1). All
patients had their baseline visit and a total of 2,286 visits over a median follow-up of 398 days
(interquartile range (IQR) 0–736). Only 38 patients (4.3%) have withdrawn from the study to
date because of will to discontinue the study (n = 11), change of physician (n = 6), lack of
response to written invitations and phone calls (n = 3), moving to a foreign country (n = 3) and
other reasons (n = 11). Four deaths have occurred. Only 5 patients (0.6%) have an overdue visit
(follow-up visit still missing after 12 months +/-45 days). The total number of internal quality
queries has been 6,802 (99.5% successfully closed).
Demographics of SMSC Patients
The total number of women and men included in the cohort at July 2015 was 586 (67.2%) and
286 (32.8%), respectively (female/male ratio = 2.0). Median age at baseline was 41.6 years (IQR
32.8–50.0) in women and 41.7 (IQR 33.6–51.3) in men (Fig 2). The vast majority of individuals
were Caucasian (n = 852, 97.7%), 11 Hispanic (1.3%), 2 African (0.2%), 3 Semite (0.3%), 1
The Swiss Multiple Sclerosis Cohort-Study
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Asian (0.1%) and 3 of other origin (0.3%). The number of patients with a family history of MS
was 110 (12.6%), of whom 96 had 1, 13 had 2 and 1 had 3 affected relatives.
Baseline Clinical Features
Baseline characteristics of all patients stratified by disease course are shown in Table 1. RRMS
represented by far the largest group (85.8%), while CIS, PPMS and SPMS accounted for 5.5%,
3.5% and 5.2% of the cohort, respectively. Four RIS and 3 NMO cases have also been recruited.
Age and disability scores were greater in patients with SPMS and PPMS than in CIS and
RRMS. The distribution of EDSS scores stratified by disease course at baseline is presented in
Fig 3.
Females had their first symptom at a slightly younger age (median 30.3 years (IQR 24.2–
38.3)) as compared to males (median 31.7 years (IQR 24.8–39.3). Age at first symptom
appeared considerably greater in PPMS than in CIS, RRMS and SPMS patients. Age at first
Fig 1. Number of recruited SMSC patients between June 2012 and July 2015.
doi:10.1371/journal.pone.0152347.g001
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symptom in PPMS appeared instead similar to age at onset of progression in SPMS patients
(Fig 4).
Clinical Changes over Follow-Up
A total of 2,286 neurological examinations with EDSS assessment have been performed (90.0%
by certified raters). Over the course of the follow-up, 9 CIS and 5 RRMS patients have con-
verted to RRMS and SPMS respectively (SPMS defined as presence of progression over at least
6 months, with or without superimposed relapses preceded by an initial period of relapsing-
remitting course). One, 2 and 3 relapses occurred in 122, 15 and 2 patients respectively (total
Fig 2. Distribution of age at baseline of all SMSC patients coloured by gender.
doi:10.1371/journal.pone.0152347.g002
Table 1. Baseline characteristics of recruited individuals stratified by diagnosis at baseline.
CIS (n = 48) RRMS
(n = 742)
SPMS (n = 45) PPMS (30) RIS (n = 4) NMO (n = 3) All (n = 872)
Female n (%) 29 (60.4) 521 (70.2) 21 (46.7) 10 (33.3) 3 (75.0) 2 (66.7) 586 (67.2)
Age median (IQR) 36.6 (28.8–
48.8)
41.0 (32.7–
48.9)
54.4 (48.6–
61.0)
53.4 (47.4–
60.6)
43.6 (35.5–
52.9)
38.4 (34.0–
50.5)
41.6 (33.1–
50.2)
Days of follow-up median
(IQR)
596.0 (123.0–
738.5)
385.5 (0.0–
734.8)
725.0 (436.0–
771.0)
378.0 (0.0–
740.8)
728.0 (651.2–
768.5)
828.0 (414.0–
844.5)
398.0 (0.0–
736.0)
Disease duration years
median (IQR)
1.3 (0.4–3.1) 8.1 (3.2–14.0) 20.8 (13.8–
29.6)
12.0 (5.2–
16.3)
NA NA 8.1 (3.1–14.4)
EDSS median (IQR) 1.5 (1.0–2.0) 2.0 (1.5–3.0) 6.0 (4.0–6.5) 4.8 (3.5–6.0) NA NA 2.0 (1.5–3.5)
doi:10.1371/journal.pone.0152347.t001
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number of relapses = 158). Median EDSS at most recent visits were 1.0 (IQR 1.0–1.5) in CIS,
2.0 (IQR 1.5–3.0) in RRMS, 6.0 (IQR 4.5–6.5) in SPMS and 5.2 (IQR 3.6–6.0) in PPMS. When
comparing baseline vs most recent visit, trends for decreasing EDSS in CIS and increasing
EDSS in RRMS patients who relapsed, PPMS and SPMS were observed. Disability in RRMS
patients without relapses after baseline has instead remained overall stable (Fig 5).
Disease Modifying Drugs
The number of individuals under treatment with specific DMDs at baseline stratified by disease
course is presented in Table 2. The proportion of patients who were untreated at baseline was
lower among RRMS (26.1%) than CIS (72.9%), PPMS (70.0%) and SPMS (53.3%) patients.
Most RRMS patients were treated with either fingolimod (33.4%) or natalizumab (24.5%),
while a smaller proportion (13.6%) was on first generation injectable DMDs. The most fre-
quently used treatments in SPMS were injectable DMDs (24.4%), fingolimod (8.9%) and
mitoxantrone (8.9%). Only 9 PPMS patients were on treatment at baseline (fingolimod n = 1,
rituximab n = 1, mitoxantrone n = 1, investigational therapies n = 6).
Table 3 provides some descriptive information regarding occurrence of relapses in RRMS
for the most frequently used DMDs. Data on relapses were available for all patients since 2
years before baseline visit. We calculated a treatment exposure time for DMDs that were initi-
ated afterwards and averaged this measure across individual patients. We then calculated the
number of clinical relapses, the number of patients experiencing a relapse within the exposure
time and the relative annualized relapse rate (ARR, i.e. number of relapses / exposure time in
years). The mean ARR progressively increased from natalizumab (0.09) to fingolimod (0.18)
Fig 3. Distribution of EDSS at baseline of all SMSC patients coloured by disease course.
doi:10.1371/journal.pone.0152347.g003
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and injectable DMDs (0.43). Some relapses have also occurred among patients on other DMDs
but sample sizes and exposure times were very small.
Biobanked Samples and MRI
A total of 2,274 serum, plasma and blood samples have been collected to date, of which 97.5%
within 8 days from the date of the visit (63,378 aliquoted specimens). There were only 12 visits
(0.5%) during which samples were not collected. There are 152 available CSF samples, of which
11 have been prospectively and 141 retrospectively collected. A total of 1,276 cranial MRI scans
were performed, of which 85.1% within 28 days from the scheduled visit.
Discussion
The SMSC is a prospective multicentre observational study collecting high quality clinical data,
MRI scans and body fluid samples in a large group of MS patients. Almost 900 individuals
were recruited between July 2012 and July 2015, for a total of 2,286 neurological examinations,
1,276 MRI scans, 2,274 blood draws and 152 collected CSF samples. The drop-out rate is
extremely low. The quality of the data is ensured through several internal controls and
Fig 4. Boxplots of age at first symptom in CIS, RRMS-SPMS (combined) and PPMS patients, together with age at onset of progression in SPMS
patients.
doi:10.1371/journal.pone.0152347.g004
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validation steps. Careful neurological examinations are performed every 6 to 12 months and
EDSS scores calculated by certified raters. The geographical characteristics of Switzerland facil-
itate regular visits, sustained long term follow-up and collaboration between different centres.
Patients were recruited using specific inclusion criteria and are not representative of the
overall Swiss MS population. We decided to include patients who were untreated, needed to
begin or switch DMD, initiated a new DMD or were currently under treatment with a second
or third generation DMD. Despite being relatively broad, the application of these criteria leads
to a bias in selection. In addition, as compared to the MS registries present in other countries
[25–27], our sample size is inevitably smaller. Despite these limitations, we highlight the
unique nature of the SMSC. Our inclusion criteria are designed to build a population of
patients which is particularly suitable for analysing factors leading to disability accumulation,
Fig 5. Boxplots of change in EDSS between baseline andmost recent visit stratified by disease course at most recent visit and presence of
relapses between baseline andmost recent visit.Only patients with at least two study visits are included.
doi:10.1371/journal.pone.0152347.g005
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treatment dynamics, DMDs efficacy and safety profile. In addition, while registries mainly col-
lect basic demographic and clinical data, the SMSC is gathering longitudinal clinical data, MRI
scans and biological samples with a drop-out rate which is currently close to 0%. This would be
economically unfeasible in much larger sample sizes and if all MS patients living in Switzerland
were included.
We believe the current follow-up is still too short to provide meaningful results, in particular
regarding disease evolution and treatment effects. We have therefore limited this manuscript
to a first comprehensive description of the data without testing any statistical hypothesis. The
sex ratio skewed towards females and the median age at first symptom in our cohort appear in
line with current knowledge [2, 28]. We could also confirm in our cohort that the age at first
symptom in PPMS is generally delayed as compared to RRMS and similar to the age at onset of
progression in SPMS [29]. RRMS and PPMS patients do not differ in terms of genetic suscepti-
bility [30] and pathological studies have not reported qualitative differences between RRMS,
SPMS and PPMS [31, 32]. Taken together, these findings suggest that onset of progression is
an age dependent process that occurs rather independently of relapses. Accordingly, in the lat-
est classification of the clinical subtypes of MS, the differences between PPMS and SPMS are
defined as relative and both forms belong to the spectrum of progressive disease [33].
Even in this short follow-up, disability scores have increased in SPMS, PPMS and RRMS
who have relapsed since baseline. In contrast, EDSS scores tended to decrease in CIS (likely
due to recovery after their first demyelinating event) and to remain stable in RRMS patients
Table 2. Number and percentage of patients under MS specific DMDs at baseline.
Treatments CIS RRMS SPMS PPMS All
n % n % n % n % n %
Fingolimod 1 2.1 248 33.4 4 8.9 1 3.3 254 29.1
Natalizumab 0 0.0 182 24.5 1 2.2 0 0.0 183 21.0
Injectable DMDs 11 22.9 101 13.6 11 24.4 0 0.0 123 14.1
Dimethyl fumarate 0 0.0 6 0.8 0 0.0 0 0.0 6 0.7
Study medication 0 0.0 2 0.3 0 0.0 6 20.0 8 0.9
Mitoxantrone 0 0.0 0 0.0 4 8.9 1 3.3 5 0.6
Azathioprine 0 0.0 2 0.3 0 0.0 0 0.0 4 0.5
Teriﬂunomide 0 0.0 3 0.4 0 0.0 0 0.0 3 0.3
Other 1 2.1 4 0.5 1 2.2 0 0.0 6 0.7
Rituximab 0 0.0 1 0.1 0 0.0 1 3.3 2 0.2
Currently no treatment 7 14.6 82 11.1 19 42.2 10 33.3 118 13.5
Treatment naive 28 58.3 111 15.0 5 11.1 11 36.7 160 18.3
All 48 100.0 742 100.0 45 100.0 30 100.0 872 100.0
doi:10.1371/journal.pone.0152347.t002
Table 3. Number of RRMS patients who initiated a DMD since 2 years before baseline, treatment exposure time, number of relapses, number of
patients experiencing a relapse and annualized relapse rate (ARR). Only DMDs used in at least 10 SMSC patients and with at least 1 year of mean fol-
low-up are shown.
Treatment Fingolimod Natalizumab Injectable DMDs
n 343 91 80
Days of exposure (mean (SD)) 642.5 (409.0) 639.5 (380.8) 496.7 (407.2)
Relapses (n) 105 17 29
Relapsing patients (n (%)) 75 (21.9) 13 (14.3) 23 (28.7)
ARR (mean (SD)) 0.18 (0.43) 0.09 (0.23) 0.43 (1.07)
doi:10.1371/journal.pone.0152347.t003
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without reported relapses. These results can be considered expected, but suggest that the meth-
ods we are using to collect clinical data are appropriately describing the complex clinical course
of this disease.
We have also provided some initial data regarding the use of DMDs. This is not representa-
tive of Switzerland and highly influenced by inclusion criteria and SMSC centres. We did not
attempt to perform efficacy analyses at this stage, but provided some preliminary findings
regarding occurrence of relapses. The relapse rate appeared lower in patients on natalizumab,
intermediate in those on fingolimod and higher in those on first generation injectable DMDs.
These represent relatively crude attempts to describe treatment data and we recommend
extreme caution in their interpretation. Appropriate analyses will need to be performed in
more homogeneous subgroups of patients using statistical methods designed for observational
studies such as propensity score based tests [34]. With longer follow-up and newly recruited
patients, we will also be able to investigate DMDs that have been more recently approved in
MS including dimethyl fumarate, teriflunomide and alemtuzumab.
To conclude, the SMSC is a new prospective multicentre observational study designed to
investigate disease evolution and new treatment options in MS. We are currently collecting
high quality longitudinal clinical data in combination with biological samples and MRI data.
The standardised follow-up schedule and rigorous quality control are unique features of our
study compared to other MS registries. This comprehensively documented long-term cohort of
patients will be an invaluable resource for rapid implementation and validation of experimental
results in MS research and improved care for MS patients.
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